Unknown

Dataset Information

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?


ABSTRACT: Minimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy. As such, its application in acute myeloid leukemia has greatly increased our ability to quantify treatment response, and to determine the chemosensitivity of the disease, as the final product of the drug schedule, dose intensity, biodistribution, and the pharmakogenetic profile of the patient. There is now consistent evidence for the prognostic power of minimal residual disease evaluation in acute myeloid leukemia, which is complementary to the baseline prognostic assessment of the disease. The focus for its use is therefore shifting to individualize treatment based on a deeper evaluation of chemosensitivity and residual tumor burden

SUBMITTER: Mosna F 

PROVIDER: S-EPMC5483867 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature